These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16923721)

  • 1. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma.
    Fujimoto Y; Mizuno T; Sugiura S; Goshima F; Kohno S; Nakashima T; Nishiyama Y
    Acta Otolaryngol; 2006 Oct; 126(10):1115-7. PubMed ID: 16923721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer.
    Kimata H; Imai T; Kikumori T; Teshigahara O; Nagasaka T; Goshima F; Nishiyama Y; Nakao A
    Ann Surg Oncol; 2006 Aug; 13(8):1078-84. PubMed ID: 16865590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
    Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
    J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma.
    Mace AT; Ganly I; Soutar DS; Brown SM
    Head Neck; 2008 Aug; 30(8):1045-51. PubMed ID: 18615711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.
    Kohno S; Luo C; Goshima F; Nishiyama Y; Sata T; Ono Y
    Urology; 2005 Nov; 66(5):1116-21. PubMed ID: 16286150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
    Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
    Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer.
    Sahin TT; Kasuya H; Nomura N; Shikano T; Yamamura K; Gewen T; Kanzaki A; Fujii T; Sugae T; Imai T; Nomoto S; Takeda S; Sugimoto H; Kikumori T; Kodera Y; Nishiyama Y; Nakao A
    Cancer Gene Ther; 2012 Apr; 19(4):229-37. PubMed ID: 22193629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
    Teshigahara O; Goshima F; Takao K; Kohno S; Kimata H; Nakao A; Nishiyama Y
    J Surg Oncol; 2004 Jan; 85(1):42-7. PubMed ID: 14696086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer.
    Nakao A; Takeda S; Shimoyama S; Kasuya H; Kimata H; Teshigahara O; Sawaki M; Kikumori T; Kodera Y; Nagasaka T; Goshima F; Nishiyama Y; Imai T
    Curr Cancer Drug Targets; 2007 Mar; 7(2):169-74. PubMed ID: 17346108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer.
    Kasuya H; Kodera Y; Nakao A; Yamamura K; Gewen T; Zhiwen W; Hotta Y; Yamada S; Fujii T; Fukuda S; Tsurumaru N; Kuwahara T; Kikumori T; Koide Y; Fujimoto Y; Nakashima T; Hirooka Y; Shiku H; Tanaka M; Takesako K; Kondo T; Aleksic B; Kawashima H; Goto H; Nishiyama Y
    Hepatogastroenterology; 2014 May; 61(131):599-605. PubMed ID: 26176043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses.
    Kimata H; Takakuwa H; Goshima F; Teshigahara O; Nakao A; Kurata T; Sata T; Nishiyama Y
    Hepatogastroenterology; 2003; 50(52):961-6. PubMed ID: 12845959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models.
    Shimoyama S; Goshima F; Teshigahara O; Kasuya H; Kodera Y; Nakao A; Nishiyama Y
    Hepatogastroenterology; 2007 Jun; 54(76):1038-42. PubMed ID: 17629034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Oncolytic virotherapy using replication-competent herpes simplex viruses].
    Nishiyama Y; Goshima F
    Uirusu; 2007 Jun; 57(1):57-65. PubMed ID: 18040155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.
    Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T
    J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Abscopal effect on metastatic tumor induced by oncolytic virus of H101 combining with local heating].
    Hu F; Hu XH; Yu P; Zhang JX; Lou GG; Liu HL; Wu B; Zhao RH; Xia HQ; Wang Y; Chen J; Ben Y; Chen SY
    Ai Zheng; 2006 Aug; 25(8):919-24. PubMed ID: 16965669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Novel treatment with oncolytic herpes simplex virus, 'HF10' against breast cancer].
    Kimata H; Teshigahara O; Nishiyama Y; Nakao A
    Nihon Rinsho; 2004 May; 62(5):987-93. PubMed ID: 15148832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma.
    Mace AT; Harrow SJ; Ganly I; Brown SM
    Acta Otolaryngol; 2007 Aug; 127(8):880-7. PubMed ID: 17763002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus.
    Wong RJ; Kim SH; Joe JK; Shah JP; Johnson PA; Fong Y
    J Am Coll Surg; 2001 Jul; 193(1):12-21. PubMed ID: 11442249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.
    Hirooka Y; Kasuya H; Ishikawa T; Kawashima H; Ohno E; Villalobos IB; Naoe Y; Ichinose T; Koyama N; Tanaka M; Kodera Y; Goto H
    BMC Cancer; 2018 May; 18(1):596. PubMed ID: 29801474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma.
    Ogawa F; Takaoka H; Iwai S; Aota K; Yura Y
    Anticancer Res; 2008; 28(6A):3637-45. PubMed ID: 19189645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.